Defunct Company
Total Trials
5
As Lead Sponsor
4
As Collaborator
1
Total Enrollment
184
NCT01062620
A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 30, 2008
Completion: Not specified
NCT01466647
A Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC)
Start: Jan 31, 2011
Completion: Sep 30, 2012
NCT01561456
Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung
Phase: Phase 2
Start: Dec 31, 2011
Completion: Dec 31, 2013
NCT01725555
A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors
Start: Oct 31, 2012
NCT01721577
Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas
Phase: Phase 1/2
Role: Collaborator
Start: Dec 31, 2012
Completion: Dec 31, 2015